Hayashi, A., Tanoshima, R., Tsujimoto, S., Yanagimachi, M., Takeuchi, M., Sasaki, K., . . . Takahashi, H. (2016). Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene. Blood Cancer J.
Παραπομπή Chicago StyleHayashi, A., et al. "Crizotinib Treatment for Refractory Pediatric Acute Myeloid Leukemia With RAN-binding Protein 2-anaplastic Lymphoma Kinase Fusion Gene." Blood Cancer J 2016.
Παραπομπή MLAHayashi, A., et al. "Crizotinib Treatment for Refractory Pediatric Acute Myeloid Leukemia With RAN-binding Protein 2-anaplastic Lymphoma Kinase Fusion Gene." Blood Cancer J 2016.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.